Commodore Capital

444 Madison Avenue
New York, NY 10022

Website: commodorecapital.com

Firm Size

• Assets Under Management (AUM):$1.4 Billion
• Number of Funds:1
• Employees:12
• Firm Type:Hedge Fund

Description

Commodore Capital is a financial investment and management firm located in New York, NY. The company specializes in providing investment solutions to high net worth individuals, institutions, and family offices. With a strong focus on identifying long-term growth opportunities, Commodore Capital executes a disciplined investment approach that aims to deliver consistent returns for its clients. The firm's experienced team of professionals conducts thorough research and analysis to uncover lucrative investment opportunities across various sectors, including technology, healthcare, real estate, and energy. Commodore Capital's investment strategies encompass both traditional and alternative investments, allowing for a diversified portfolio that mitigates risk and maximizes returns. In addition to its investment advisory services, Commodore Capital offers comprehensive wealth management solutions tailored to meet the individual needs and goals of its clients. This includes personalized financial planning, asset allocation, risk management, and estate planning services. Commodore Capital is known for its commitment to providing exceptional client service. The firm believes in building long-term partnerships with its clients by offering transparent communication, timely execution, and continuous portfolio monitoring. By aligning its interests with those of its clients, Commodore Capital strives to create a trusted and collaborative environment. Overall, Commodore Capital is a reputable financial firm that combines its expertise in investment management with a dedication to delivering customized solutions to its discerning clientele.

Latest News

Powered by

Dec 07, 2023: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Access Biotechnology, Venrock Healthcare Capital Partners, Perceptive Advisors, RTW Investments, LP, Braidwell LP, Fairmount, Cormorant Asset Management, Polar Capital, Boxer Capital, Deep Track Capital, Great Point Partners LLC, Affinity Asset Advisors, Commodore Capital, Woodline Partners LP, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.